Mental HealthNeurology & Headache Medicine

Migraine vs. Tension Headache: Aura, CGRP Pathway, Triggers, and Abortive Treatments

Headaches are among the most common neurological complaints, but treating a migraine as a tension headache frequently results in medication overuse and treatment failure. Review the pathophysiology of the trigeminovascular system, sensory auras, diagnostic criteria (ICHD-3), acute abortive treatments (triptans, gepants), and modern CGRP monoclonal antibodies.

Published: 2026-09-04Reviewed: September 2026Updated: 2026-09-15 9 min read 2010 Views
Listen to this guide Audio Edition

Hands-free audio narration

Educational Health Notice

This educational guide is researched in accordance with our Editorial Policy and public health guidelines. It is not personal medical advice. For clinical questions, read our Medical Disclaimer or consult a qualified healthcare provider.

Migraine vs. Tension Headache: Aura, CGRP Pathway, Triggers, and Abortive Treatments

Quick Summary & Key Findings

Tension-type headaches present as a bilateral, dull, non-pulsatile 'tight band' around the head without nausea or light sensitivity, worsened by muscle tension and posture. Migraines are neurovascular events characterized by moderate-to-severe unilateral throbbing pain, sensory hypersensitivity (photophobia, phonophobia), nausea/vomiting, and worsening with routine physical movement, with 25–30% preceded by visual or sensory auras. Acute migraine treatments include triptans (sumatriptan) and CGRP antagonists (rimegepant, ubrogepant).

Headache disorders rank among the top ten causes of disability worldwide, with migraine affecting over one billion individuals globally. Despite their prevalence, primary headache disorders are frequently misdiagnosed. Many patients who experience facial pressure and nasal congestion assume they have 'sinus headaches,' when clinical evaluation confirms over 80% are actually migraines.

Unlike tension headaches—which stem primarily from pericranial myofascial tension and heightened central pain sensitivity—a migraine is a complex neurological disorder involving genetically predisposed brain hypersensitivity, cortical spreading depression, and activation of the trigeminovascular system with release of inflammatory neuropeptides.

Accurately classifying headache pathology allows patients to bypass ineffective over-the-counter painkillers and utilize targeted neurochemical abortive and preventive medications.

Diagnostic Differentiation: ICHD-3 Criteria

The International Classification of Headache Disorders (ICHD-3) outlines precise diagnostic criteria separating migraines from tension-type headaches:
Location & Quality: Tension headaches are bilateral, presenting as a constant, non-throbbing, vice-like pressing band around the temples or forehead. Migraines are typically unilateral (one-sided) and pulsating/throbbing in rhythm with the heartbeat.
Associated Sensory Symptoms: Migraines feature sensory amplification: photophobia (light sensitivity), phonophobia (sound sensitivity), osmophobia (smell sensitivity), and nausea or vomiting. Tension headaches lack nausea and may have at most mild photophobia OR phonophobia, but never both.
Effect of Routine Movement: Migraine pain worsens significantly with walking up stairs, bending over, or moving the head, forcing patients to lie still in a dark, quiet room. Tension headaches are not aggravated by routine physical activity.
Duration: Tension headaches last from 30 minutes to 7 days. Untreated migraines last 4 to 72 hours.

Neurobiology: Cortical Spreading Depression and CGRP

A migraine involves distinct neuroelectrical and neurochemical phases:
The Migraine Aura: In ~25% of patients, a wave of transient neuronal and glial depolarization called 'cortical spreading depression' travels across the cerebral cortex, producing visual scintillating scotomas (flashing zigzag lines), blind spots, or unilateral finger/face tingling lasting 20 to 60 minutes before the headache begins.
Calcitonin Gene-Related Peptide (CGRP): Activation of the trigeminal nerve releases CGRP and substance P around meningeal blood vessels, triggering neurogenic inflammation, vasodilation, and throbbing pain signals sent to the brainstem.

Modern Acute Abortive and Preventive Therapies

Headache medicine has advanced from non-specific analgesics to receptor-targeted treatments:
Triptans (Sumatriptan, Zolmitriptan, Rizatriptan): 5-HT1B/1D serotonin receptor agonists that constrict meningeal vessels and block neuropeptide release; take at the earliest onset of headache phase (not during aura).
Small-Molecule CGRP Antagonists ('Gepants' - Rimegepant, Ubrogepant): Oral acute medications that block CGRP receptors without causing vasoconstriction, making them safe for patients with cardiovascular disease or triptan contraindications.
CGRP Monoclonal Antibodies (Erenumab, Galcanezumab, Fremanezumab): Monthly subcutaneous injections that prevent frequent episodic and chronic migraines (>8 headache days/month).
Medication Overuse Headache (MOH) Warning: Taking simple analgesics (NSAIDs, acetaminophen) on >15 days/month or triptans/combination pills on >10 days/month triggers rebound chronic daily headaches.

Frequently Asked Questions

N
Clinical Reviewer License Verified

Dr. Nimesh G. Desai, MBBS, MD, DPM

Senior Consultant Psychiatrist & Former Director, IHBAS Delhi • MBBS, MD (Psychiatry), DPM
Medical Review Board

Dr. Nimesh G. Desai is a renowned neuropsychiatrist and the former Director of the Institute of Human Behaviour and Allied Sciences (IHBAS), Delhi. With over 35 years in academic psychiatry, community mental health, and neurological wellness, he oversees clinical mental health guides at mediguide4u.

License ID: DMC-08192
Senior Consultant Psychiatrist & Former Director, Institute of Human Behaviour and Allied Sciences (IHBAS), Dilshad Garden, Delhi
Medically evaluated on September 2026View Dr. Profile, Verified Credentials & Articles

References & Clinical Resources

  1. Clinical Research Faculty & Editorial Team. The International Classification of Headache Disorders 3rd Edition (ICHD-3) (2020-2026). [Access Resource Link] — Cephalalgia / International Headache Society
  2. Clinical Research Faculty & Editorial Team. The American Headache Society Consensus Statement: Update on Integrating New Migraine Treatments into Clinical Practice (2020-2026). [Access Resource Link] — Headache: The Journal of Head and Face Pain
  3. Clinical Research Faculty & Editorial Team. Calcitonin Gene-Related Peptide (CGRP) and Migraine Pathophysiology (2020-2026). [Access Resource Link] — Nature Reviews Neurology
Article Tools & Sharing:
Educational Resources
Patient Community Doctor Reviewed

Reader Reviews & Clinical Q&A

Real experiences, reader questions, and verified physician guidance.

5.0 out of 5 (2 reviews)
JF
Jonathan F., Software EngineerVerified Reader
•August 18, 2026

The neurobiological breakdown of the HPA axis, cortisol dysregulation, and amygdala reactivity helped me understand that chronic burnout is a physiological condition, not a personal failing.

Dr. Samir Parikh, MBBS, MD (Psychiatry)Psychiatrist & Director of Mental Health
August 19, 2026

Understanding the biological basis of chronic autonomic nervous system stress helps dismantle shame and guides effective, restorative recovery protocols, Jonathan.

MK
Megan K., Licensed Professional CounselorMental Health Professional
•August 29, 2026

Clear, compassionate, and scientifically rigorous. The comparison between cognitive behavioral exposure therapy and pharmacotherapy provides great balanced guidance for my clients.

Dr. Samir Parikh, MBBS, MD (Psychiatry)Psychiatrist & Director of Mental Health
August 30, 2026

Thank you, Megan. Presenting both psychotherapy and evidence-based medical treatments neutrally allows individuals to make informed collaborative decisions with their providers.

Leave a Review or Ask a Medical Question

5 / 5 Stars
* Reviews are reviewed by our clinical editorial team in accordance with our medical policies.